Skip to main content

RhDNase I

Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion

  • RegistryNCT07361224
  • PhasePhase 1
  • StatusRecruiting
  • ConditionLarge B-Cell Lymphoma (LBCL)
  • SponsorTel-Aviv Sourasky Medical Center
How RhDNase I worksNCT073612241 min

What the film says

Read the transcript

When large B-cell lymphoma keeps growing right up to the day CAR T therapy begins, most patients relapse within a year.

The idea: clear the debris that shields the tumor, so the CAR T cells can reach it.

Neutrophils can throw out sticky webs of DNA called NETs. In lymphoma, those webs feed tumor growth, track with worse outcomes, and may block T cells. CLS-015 is a recombinant DNase, an enzyme that digests them, given by vein five times over the two weeks after a standard CD19 CAR T infusion.

A small first safety study at Sourasky Medical Center in Tel Aviv, for patients still progressing at lymphodepletion. Ron Ram leads it. Public record; not medical advice.

Sources behind this film

The drug

What is being tested.

CLS-015 IV infusions after CAR-T infusion done on Days 0,3,6,10 and 15 after CAR-T infusion

Disease progression in large B-cell lymphoma is a major obstacle to successful CAR-T therapy, with approximately 40% of patients experiencing disease progression within 3 months of CAR-T infusion and 60% of patients experiencing disease progression within the first year.

While patients with large B-cell lymphoma in partial response or complete response during lymphodepletion have a progression-free survival (PFS) of 60-80% at 1 year, patients with stable disease (SD) or progressive disease (PD) in the lymphodepletion phase have a poor PFS of 20-30%.

The study

How the trial runs.

This is a Phase 1, single-center, open-label study to evaluate the safety of CLS-015 in combination with anti-CD19 CAR-T therapy in patients with large B-cell lymphoma. The goal is to improve clinical response by reversing the negative effects of NETs on immune function and CAR-T cells.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Participant must be at least 18 years of age inclusive, at the time of signing the informed consent.
  • Large B-Cell lymphoma treated with CAR-T targeting CD19 (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel)
  • Stable Disease or Progressive Disease confirmed by PET-CT on the day of lymphodepletion
  • Capable of giving signed informed consent
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.